中国肝脏病杂志（电子版）
中國肝髒病雜誌（電子版）
중국간장병잡지（전자판）
CHINESE JOURNAL OF LIVER DISEASES(ELECTRONIC VERSION)
2014年
2期
13-17
,共5页
王柏芳%王颖%王炳元%温博%高君
王柏芳%王穎%王炳元%溫博%高君
왕백방%왕영%왕병원%온박%고군
肝硬化%失代偿期%异甘草酸镁%安全性
肝硬化%失代償期%異甘草痠鎂%安全性
간경화%실대상기%이감초산미%안전성
Liver cirrhosis%Decompensated%Magnesium isoglycyrrhizinate%Safty
目的：探讨失代偿期肝硬化（DLC）患者应用异甘草酸镁（MIG）注射液保肝治疗的安全性。方法回顾性总结单用MIG或合用其他保肝药物（限2种以内）治疗2周以上、血清离子和血压测定完整的118例DLC患者，男性81例，女性37例，年龄14～84岁，平均年龄（54.6±12.7）岁。其中病毒性肝炎相关肝硬化（VRC）52例，酒精性肝硬化（AC）35例，自身免疫相关肝硬化（ARC）31例。分析治疗1、2周患者血清离子和收缩压（SBP）、舒张压（DBP）的变化。结果 DLC患者治疗1周血清K离子（P =0.015）和Ca离子（P =0.016）均较治疗前增加；其余指标比较，差异均无统计学意义；VRC和AC患者无论是治疗1周还是2周后，所有血清离子改变均无统计学意义；ARC患者治疗1周后，K离子比治疗前在正常范围内略有增加（P=0.043）外，其他指标变化均无统计学意义。DLC和VRC患者治疗1周后，SBP均降低（P =0.007、0.027），DBP无变化；其他两组SBP或DBP均无明显变化。结论无论MIG单用或合用其他保肝药物治疗两周，均没有发现DLC患者水钠潴留和血压升高，短期应用是安全的。
目的：探討失代償期肝硬化（DLC）患者應用異甘草痠鎂（MIG）註射液保肝治療的安全性。方法迴顧性總結單用MIG或閤用其他保肝藥物（限2種以內）治療2週以上、血清離子和血壓測定完整的118例DLC患者，男性81例，女性37例，年齡14～84歲，平均年齡（54.6±12.7）歲。其中病毒性肝炎相關肝硬化（VRC）52例，酒精性肝硬化（AC）35例，自身免疫相關肝硬化（ARC）31例。分析治療1、2週患者血清離子和收縮壓（SBP）、舒張壓（DBP）的變化。結果 DLC患者治療1週血清K離子（P =0.015）和Ca離子（P =0.016）均較治療前增加；其餘指標比較，差異均無統計學意義；VRC和AC患者無論是治療1週還是2週後，所有血清離子改變均無統計學意義；ARC患者治療1週後，K離子比治療前在正常範圍內略有增加（P=0.043）外，其他指標變化均無統計學意義。DLC和VRC患者治療1週後，SBP均降低（P =0.007、0.027），DBP無變化；其他兩組SBP或DBP均無明顯變化。結論無論MIG單用或閤用其他保肝藥物治療兩週，均沒有髮現DLC患者水鈉潴留和血壓升高，短期應用是安全的。
목적：탐토실대상기간경화（DLC）환자응용이감초산미（MIG）주사액보간치료적안전성。방법회고성총결단용MIG혹합용기타보간약물（한2충이내）치료2주이상、혈청리자화혈압측정완정적118례DLC환자，남성81례，녀성37례，년령14～84세，평균년령（54.6±12.7）세。기중병독성간염상관간경화（VRC）52례，주정성간경화（AC）35례，자신면역상관간경화（ARC）31례。분석치료1、2주환자혈청리자화수축압（SBP）、서장압（DBP）적변화。결과 DLC환자치료1주혈청K리자（P =0.015）화Ca리자（P =0.016）균교치료전증가；기여지표비교，차이균무통계학의의；VRC화AC환자무론시치료1주환시2주후，소유혈청리자개변균무통계학의의；ARC환자치료1주후，K리자비치료전재정상범위내략유증가（P=0.043）외，기타지표변화균무통계학의의。DLC화VRC환자치료1주후，SBP균강저（P =0.007、0.027），DBP무변화；기타량조SBP혹DBP균무명현변화。결론무론MIG단용혹합용기타보간약물치료량주，균몰유발현DLC환자수납저류화혈압승고，단기응용시안전적。
Objective To investigate the safty of MIG in anti-inflammatory and hepatoprotective therapy of patients with decompensated liver cirrhosis (DLC). Methods There are 118 cases with decompensated cirrhosis treated with magnesium isoglycyrrhizinate (80 mg/day) (MIG) alone or combined with other one or two kinds of hepatoprotective drugs treatment above two weeks retrospectively. The blood ions and blood pressure were measured completely, and the male patients were 81 cases and famale patients were 37 cases, while the average age was (54.6 ± 12.7) (14-84) years old. Among total of 118 patients, there were 52 cases of virus-related cirrhosis (VRC), 35 cases of alcoholic cirrhosis (AC) and 31 cases of autoimmune-related cirrhosis (ARC). The difference of serum ions and systolic blood pressure (SBP), as well as diastolic blood pressure (DBP) at the ifrst and second week were tested and analysed. Results To patients on DLC, there was a signiifcant increase in the normal range about blood potassium (P=0.015) and calcium (P=0.016) respectively than that before the therapy, while no increase showed on the other parameters. All the patients on VRC and AC had no meaningful change in serum ions no matter they got on therapy after one week or two. Slight increase showed on blood potassium (P=0.043) of patients with ARC in the normal range after a week’s therapy, while no difference relfected on other parameters signiifcantly. DLC and VRC patients had meaningful reduction on SBP (P=0.007, 0.027) after they went on MIG theray after one week, while no difference on DBP and no signiifcant changes relfected on the other two groups. Conclusions Whether MIG alone or in combination with the other anti-inlfammatory medications about two weeks, observers didn’t ifnd water-sodium retention and blood pressure elevation on the patients with DLC, therefore, short-term treatment of MIG ensures safty.
